Mode
Text Size
Log in / Sign up

Remimazolam shows comparable sedation success and better hemodynamic stability versus propofol in fiberoptic bronchoscopyRemimazolam keeps breathing steadier during bronchoscopy than propofol

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider remimazolam for bronchoscopy sedation; it offers better hemodynamic stability and less hypoxemia than propofol in small retrospective data.

The study evaluated the safety and efficacy of remimazolam versus propofol for sedation during fiberoptic bronchoscopy in patients maintaining spontaneous breathing. Both agents achieved a comparable success rate for maintaining adequate sedation throughout the procedure. However, the remimazolam group exhibited higher oxygen saturation levels at several time points and experienced a lower incidence of hypoxemia compared with the propofol group.

In terms of tolerability, remimazolam was associated with a lower rate of injection pain and fewer episodes of hypotension. Recovery time was shorter in the remimazolam group, though the authors note this may be influenced by the routine administration of flumazenil. Satisfaction scores among endoscopists and patients were similar between the two treatment arms.

The authors highlight several limitations, including the retrospective nature of the analysis and the relatively small number of participants. Furthermore, the study population consisted exclusively of patients with low American Society of Anesthesiologists physical status classifications. These constraints suggest that the observed benefits require validation in larger, prospective trials before broad clinical adoption.

This doesn’t mean this treatment is available yet.

Why oxygen levels matter during bronchoscopy

During bronchoscopy, the scope can briefly block part of your airway. If sedation makes you too sleepy, oxygen levels can drop. Doctors watch oxygen saturation (SpO2) closely. They also watch blood pressure, because some sedatives can cause it to fall. And they want to avoid injection pain, which can make the experience uncomfortable.

Think of your airway like a highway. The scope is a car entering the lane. Sedation is the traffic controller. If the controller slows things too much, cars back up. The goal is smooth flow: you stay relaxed, but your breathing keeps moving.

How remimazolam works in the body

Remimazolam is like a key that fits a specific lock in the brain. It turns down activity to ease anxiety and discomfort. What makes it different is speed: the body has an enzyme that quickly breaks the key apart, so the effect fades fast. That quick metabolism may help people wake up sooner and may reduce lingering side effects.

Propofol works differently. It’s more like a dimmer switch for brain activity. It can be very effective, but it may also slow breathing and drop blood pressure more often.

What the study looked at

Researchers reviewed charts from October 2024 to October 2025. They included adults having fiberoptic bronchoscopy with sedation that preserved spontaneous breathing. They compared two groups: remimazolam and propofol. The main question was simple: did the sedation work as intended? They also looked at oxygen levels, blood pressure, pain, and recovery time.

The study included 76 patients in total: 36 in the remimazolam group and 40 in the propofol group. All were relatively healthy adults (ASA I–II), meaning they didn’t have major other illnesses.

Both groups had a 100% sedation success rate. In other words, the sedation worked for everyone.

Oxygen levels were higher in the remimazolam group at the start and at 5, 10, and 15 minutes into the procedure. The difference was statistically significant, meaning it was unlikely due to chance.

Fewer people in the remimazolam group had low oxygen levels: about 17% compared to 35% with propofol. Injection pain was also lower: none in the remimazolam group versus about 18% with propofol. Low blood pressure was less common too: about 6% versus 23% with propofol.

Recovery time was shorter in the remimazolam group. But there’s a catch: the researchers noted that reversal medication (flumazenil) was used routinely in that group, which can speed up wake-up. So the faster recovery may not be solely due to remimazolam itself.

Onset time and satisfaction scores were similar between the two groups.

If you’re scheduled for bronchoscopy and want to know your sedation options, ask your doctor whether remimazolam might be appropriate. It appears to offer similar success with fewer side effects in this study, especially for oxygen levels and injection pain. However, this was a small, retrospective study, and the recovery time finding may be influenced by reversal drug use.

Availability can vary by hospital and country. Remimazolam is newer and may not be used for bronchoscopy everywhere. Your doctor will consider your health history, medications, and the specific procedure.

Limitations to keep in mind

This study was retrospective, meaning it looked back at charts rather than assigning treatments in advance. The sample size was small, and only relatively healthy adults were included. Recovery time differences may be confounded by routine flumazenil use. Larger, prospective studies are needed to confirm these findings.

What happens next

Researchers will need larger, prospective trials to validate these results and to clarify whether remimazolam’s recovery advantage holds without routine reversal. If confirmed, remimazolam could become a more common choice for bronchoscopy sedation, especially for patients at higher risk of low oxygen or blood pressure. For now, talk with your doctor about the best sedation plan for your situation.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
Background and ObjectivesAdequate sedation with preserved spontaneous breathing and stable hemodynamics is critical for the success and safety of fiberoptic bronchoscopy (FOB). Remimazolam, a novel ultra-short-acting benzodiazepine with rapid metabolism and favorable sedative profiles, has shown promising sedative effects for procedural sedation. However, comparative data on its application in FOB with preserved spontaneous breathing remain limited. This retrospective study aimed to compare the safety and efficacy of remimazolam and propofol for sedation in patients undergoing FOB with preserved spontaneous breathing.Materials and MethodsA retrospective chart review was conducted from October 2024 to October 2025. All patients undergoing FOB with preserved spontaneous breathing were enrolled. Patients were divided into two groups based on the sedative used: remimazolam (Group R) and propofol (Group P). The primary outcome was the sedation success rate. Secondary outcomes included hemodynamic parameters, incidence of adverse events, anesthesia-related times, satisfaction scores of endoscopists and patients.ResultsThirty-six patients in group R and Forty in group P were collected in this retrospective study. Sedation success rate was 100% in both groups. Oxygen saturation (SpO2) levels were higher in group R at beginning of the bronchoscopy, 5, 10, and 15 min after the start of bronchoscopy (P = 0.012, 0.001, 0.017, and 0.006, respectively). Group R had a lower incidence of hypoxemia (16.67% vs. 35.0%, P = 0.034), injection pain (0% vs. 17.5%, P = 0.008), and hypotension (5.56% vs. 22.5%, P = 0.036). Recovery time was shorter in group R (P = 0.017). Onset time, and satisfaction scores were comparable in the two groups.ConclusionOur study uncovered remimazolam demonstrates a comparable success rate to propofol and exhibits favorable safety profiles, including reduced hypoxemia, injection pain, and hypotension during FOB with preserved spontaneous breathing. However, the shorter recovery time in Group R was confounded by the routine use of flumazenil, and the findings are limited by the retrospective design, small sample size and exclusive enrollment of ASA I–II patients, requiring validation in larger, prospective studies.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.